AstraZeneca PLC
AZN
$192.48
-$0.02-0.01%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.63% | 13.52% | 15.00% | 15.48% | 18.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.63% | 13.52% | 15.00% | 15.48% | 18.03% |
| Cost of Revenue | 11.50% | 1.78% | 16.85% | 15.56% | 19.88% |
| Gross Profit | 8.01% | 16.21% | 14.60% | 15.46% | 17.64% |
| SG&A Expenses | 3.18% | 2.47% | 4.97% | 5.06% | 7.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -16.84% | -40.99% | 6.74% | 76.08% | 81.45% |
| Total Operating Expenses | 8.03% | 5.82% | 10.99% | 12.59% | 15.84% |
| Operating Income | 10.54% | 40.67% | 28.64% | 25.25% | 25.62% |
| Income Before Tax | 42.70% | 44.40% | 29.40% | 24.96% | 25.97% |
| Income Tax Expenses | 31.45% | 43.11% | 32.28% | 37.36% | 75.91% |
| Earnings from Continuing Operations | 45.33% | 44.68% | 28.81% | 22.80% | 18.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -33.33% | 0.00% | -40.00% | -66.67% | 0.00% |
| Net Income | 45.34% | 44.71% | 28.80% | 22.76% | 18.14% |
| EBIT | 10.54% | 40.67% | 28.64% | 25.25% | 25.62% |
| EBITDA | 9.75% | 23.35% | 21.00% | 18.18% | 18.15% |
| EPS Basic | 45.25% | 44.61% | 28.72% | 22.72% | 18.12% |
| Normalized Basic EPS | 11.36% | 44.92% | 32.35% | 29.23% | 29.12% |
| EPS Diluted | 45.29% | 44.97% | 28.81% | 22.35% | 17.74% |
| Normalized Diluted EPS | 11.43% | 44.99% | 32.38% | 29.19% | 29.09% |
| Average Basic Shares Outstanding | 0.06% | 0.06% | 0.06% | 0.03% | 0.02% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.05% | 0.06% | 0.05% |
| Dividend Per Share | 3.23% | 5.39% | 5.39% | 6.90% | 6.90% |
| Payout Ratio | -0.26% | -0.26% | -0.14% | -0.10% | -0.13% |